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Background: Vertebral metastases are associated with significant pain, disability, and morbidity. 
Open surgery for fracture stabilization is often inappropriate in this cancer population due to a 
poor risk-benefit profile, particularly if life expectancy is short. Vertebroplasty and kyphoplasty are 
appealing adjunctive procedures in patients with malignancy for alleviation of intractable pain. 
However, these patients have a higher risk of serious complications, notably cement extravasation. 
Study Design: We prospectively evaluated clinical results of polyetheretherketone (PEEK) implant 
(Kiva) assisted vertebroplasty performed in malignant painful osteolytic lesions at risk for cement 
extravasation due to vertebral wall involvement.
Setting: Department of Interventional Radiology, Institute for Cancer Research and Treatment, 
Candiolo, Turin, Italy
Methods: Forty patients (22 women; mean age 66.8 ± 12.4), suffering from a painful spine 
malignancy with vertebral wall involvement not responding to conventional therapies and without 
surgical indications, underwent vertebral augmentation with Kiva intravertebral implant for pain 
palliation. The procedure was performed with moderate sedation and local anesthesia under 
combined digital fluoroscopy and computed tomography guidance. After the coil-shaped PEEK 
implant was deployed within the vertebral lesion, bone cement was injected under continuous 
digital fluoroscopic control. Patients were discharged from the hospital the next procedural day. 
The Visual Analog Scale (VAS) for pain, Oswestry Disability Index (ODI), analgesic requirement, and 
use of external brace support were evaluated to determine efficacy. The primary end-point was 
safety and efficacy at one month after the procedure. However, all the patients were scheduled 
to be followed-up at month 3, 6, and every 6 months thereafter. Follow-up was prospectively 
evaluated in all patients after Kiva with clinical interviews. The Institution’s Internal Review Board 
approved this study.
Results: Median pre-treatment VAS of 10 (range 6 – 10) significantly (P < 0.001) dropped to 
one (range 0 – 3), with all patients achieving a clinically relevant benefit on pain at one month. 
Differences in pre- and post-treatment analgesic therapy were significant (P < 0.001). All patients 
no longer use an external brace after Kiva. In 7 out of 43 (16.3%) treated vertebrae a bone cement 
leakage was detected. 
Limitations: This is a not randomized study. Participants were limited to 40 patients.
Conclusion: The Kiva System potentially represents a novel and effective minimally invasive 
treatment option for patients suffering from severe pain due to osteolytic vertebral metastases. 
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management. Several studies have reported dramatic 
improvements in pain severity associated with osteo-
lytic vertebral metastases following percutaneous ver-
tebral augmentation (13-16). However, percutaneous 
vertebral augmentation is associated with a higher risk 
of complications from PMMA extravasation in cancer 
patients compared to osteoporotic patients due to loss 
of cortical integrity (8). Leakages can be reduced but 
may always occur even with new high viscosity PMMA 
(17). As such, malignancy is widely considered a rela-
tive contraindication for these procedures. We report 
our personal experience in vertebral augmentation of 
painful osteolytic vertebral metastases with vertebral 
wall involvement treated by a novel coil-shaped poly-
etheretherketone (PEEK-OPTIMA) implant designed to 
internally contain and thus minimize the risk of PMMA 
extravasation.
Methods
Population and Study Design
From February 2010 to January 2012, 40 patients 
(22 women; mean age 66.8 ± 12.4 years) suffering from 
spine malignancy (9 myeloma and 31 metastasis) were 
treated with percutaneous vertebral augmentation as-
sisted by placement of 43 PEEK endovertebral devices 
(3 patients were treated at 2 vertebral levels) at a single 
institution. Patients were informed of potential treat-
ment-related complications and each provided signed 
informed consent in accordance with the Declaration 
of Helsinki. Outcome assessments were collected pro-
spectively and the institution’s Internal Review Board 
approved this analysis.
Inclusion Criteria
•	 Age	≥	40	years	old
•	 Metastasis	 with	 bone	 marrow	 edema	 within	 the	
vertebra assessed with magnetic resonance imag-
ing (MRI) 
•	 Osteolytic	metastasis	 with	 vertebral	 wall	 involve-
ment assessed with CT
•	 Significant	back	pain	(Visual	Analogue	Scale	score	
≥	5)
•	 Tenderness	 to	palpation	over	 the	 spinous	process	
of the fractured vertebra
•	 Back-pain	persistence	after	a	minimum	of	4	weeks	
of conservative medical treatment.
Exclusion Criteria 
•	 Systemic	 infection	 or	 any	 suspicious	 infective	
Percutaneous	vertebroplasty	 (PV)	 consists	of	 the	injection of polymethylmethacrylate (PMMA) into a collapsed vertebra in order to obtain 
pain relief and mechanical strengthening of the 
vertebral body. Galibert and Deramond proposed this 
procedure for the treatment of aggressive vertebral 
hemangiomas of C2 (1) and, at present, it is used 
extensively worldwide in osteoporotic and malignant 
vertebral fractures when conventional therapies are 
not	 effective	 or	 not	well	 tolerated.	 Although	 PV	 has	
been shown in multiple prospective randomized 
studies to be a relatively safe and effective procedure 
for back-pain treatment, several authors have reported 
some major complications that can lead to paraplegia 
and death (2,3). Most of the described complications 
concerned pulmonary embolism, soft tissues damages, 
and nerve root compression related to the leakage 
of	 bone	 cement	 (4,5).	With	 fluoroscopic	 observations	
bone cement leakage can be detected frequently in 
vertebroplasty	 as	 it	 occurs	 in	 38%	 (6)	 to	 72.5%	 (7,8)	
of	 patients	 with	 vertebral	 metastases,	 in	 59.5%	 (9)	
and	 65%	 (10)	 of	 patients	with	 osteoporotic	 vertebral	
collapse or, even more, in 81% of treated patients 
(11) when computed tomography (CT) is carried out 
after	PV.	Even	if	this	frequent	minimal	leakage	is	well	
tolerated or asymptomatic in the large majority of 
patients, cement extravasation is the main source of 
clinically relevant complications depending upon site 
and volume of leakage.
Vertebral	metastases	are	associated	with	significant	
pain, disability, and morbidity. If left untreated, pro-
gression of these lesions result in painful microfractures 
with potential for vertebral level collapse and spinal 
cord compromise. Open surgery for fracture stabiliza-
tion is often inappropriate in this patient population 
due to a poor risk-benefit profile. Given that the aver-
age life expectancy in patients with vertebral metastasis 
is one year (12), surgery is undesirable since the postop-
erative recovery consumes much of the remainder of 
life. Therefore, non-operative and minimally invasive 
techniques are the most appropriate treatment options 
for vertebral metastases.
Percutaneous vertebral augmentation is a mini-
mally invasive procedure involving the injection of 
polymethylmethacrylate (PMMA) into a vertebral 
body that is either partially collapsed or at high risk 
for	collapse	due	to	osteolysis.	Vertebral	augmentation	
is appealing as an adjunct to radiotherapy or chemo-
therapy in patients with malignancy for alleviation of 
intractable pain despite comprehensive nonoperative 
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•	 Uncorrectable	coagulation	disorders
•	 Nerve	root	pain	or	neurological	deficit	due	to	the	
fracture or cord compression by the tumor.
In all patients MRI, spiral CT with multiplanar re-
construction (MPR) and x-ray revealed an osteolytic 
vertebral metastasis with involvement of vertebral body 
extending to the cortical vertebral wall either anteriorly 
and/or posteriorly (Fig. 1).
Technique
Immediately prior to the procedure, the patient was 
premedicated with intravenous antibiotics (vancomycin 
hydrochloride 1 gm and gentamycin 100 mg).  The pa-
tient was placed prone on the angiographic suite table 
and the procedure was carried out with hybrid digital 
fluoroscopic and CT guidance. The entire procedure was 
performed under local anesthesia (3 mL of 2% lidocaine 
hydrocloride at the skin level and deep to include the 
periostium) along with continuous monitoring of vital 
parameters.
Using	an	11-gauge	needle	inserted	either	through	
the costotransversal route (extrapedicular) in the tho-
racic spine or transpedicular approach in the lumbar 
spine, the upper endplate of vertebral body just lateral 
to the midline was targeted. A Kirschner guide-wire was 
inserted to allow the placement of a 6-gauge working 
cannula (Fig. 2 top row) just below the superior end-
plate directed medially.
The delivery system was inserted through the 
6-gauge introducer to allow the deployment of its ni-
tinol coil-shaped guide-wire into the central vertebral 
body. The Kiva implant was then delivered over the 
nitinol guide-wire inside the osteolytic lesion of the 
vertebra to form a nesting, cylindrical column; correct 
positioning of the device was confirmed by rotational 
acquisition with MPR (Fig. 2 bottom row). 
Up	to	4	loops	of	the	implant	were	inserted	into	the	
vertebral body for a maximum coil stack of 12 mm, which 
re-elevates the endplate. After the coil is retracted, the 
radiopaque bone cement can be gradually injected using 
a manual screw injector through the Kiva implant and 
its inner channel under fluoroscopic monitoring (Fig. 3 
top row). Post-procedural radiographs and CT scan with 
MPR were then performed to demonstrate a satisfactory 
bone cement distribution within the vertebral body and 
to detect if even minimal bone cement extravasation 
has occurred (Fig. 3 bottow row).
Device
The	PEEK	implant	is	part	of	the	Kiva	VCF	Treatment	
System	(Benvenue	Medical,	Inc.,	Santa	Clara,	CA,	USA)	
and is offered in a kit containing an access needle, 
Kirschner guide-wire, dilator with working cannula, 
delivery system with nitinol coil guide-wire, and the 
implant bone cement and its manual screw injection 
system. The Kiva System received CE Mark approval in 
December 2008 and is currently under investigation for 
FDA	approval	in	the	United	States.
Bone Cement Leakage Assessment
Bone cement extravasation was studied im-
mediately after vertebral augmentation with MPR 
reconstructed from angiographic data  (Allura X-per 
CT,	 Philips,	 The	 Netherlands).	 Two	 independent	 radi-
ologists, blinded to clinical outcomes, performed CT 
evaluations.
Fig. 1. Preoperative imaging demonstrating osteolytic vertebral metastasis with complete involvement of  the T10 vertebral body, 
extending to the cortical vertebral wall posteriorly, and partial of  T9 and T11 also. T1, T2, T2-weighted Short Tau Inversion 
Recovery (STIR) magnetic resonance imaging, computed tomography and x-ray.
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Fig. 2. Intraoperative images demonstrating access with 11-gauge needle, introduction of  the dilator, placement of  working cannula 
in lateral and anteroposterior view (upper row) and Kiva nitinol coil, deployed PEEK implant in lateral and anteroposterior view, 
rotational acquisition with multiplanar reconstruction to check correct placement (lower row).
Fig. 3. Completed procedure with ce-
ment filled Kiva implant. X-ray and 
reformatted postoperative computed 
tomography scan demonstrating satis-
factory bone cement distribution within 
the T10 vertebral body and the absence 
of  extravasation either anteriorly or 
posteriorly.
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Clinical Evaluation
Pain was evaluated at each patient visit by the 
11-point	pain	intensity	numerical	rating	Visual	Analog	
Scale	 (VAS)	 where	 0	 represents	 no	 pain	 and	 10	 the	
worst experienced pain. Patients were asked to rate 
their worst pain experienced during the prior 3 days. 
Analgesic drugs prescribed at baseline and at follow-up 
visits were classified as none, non-steroidal anti-inflam-
matory	drugs	(NSAIDs),	and	oral	narcotic,	transdermal	
or intravenous narcotic.
Pain and analgesic drug use were assessed and 
recorded for all the patients at 3 time points: baseline 
(pre-procedure), 2 weeks, and 3 months post-procedure. 
Staff anesthesiologists performed these assessments 
during an office visit. Additionally, we recorded the use 
of external braces at baseline and 3 months after the 
procedure. Patients were then followed up by office 
visits (at 6 months and every 6 months thereafter) and 
any	 change	 in	VAS	 scores	was	 recorded.	 If	new	onset	
back pain was reported during routine clinical inter-
view the patient was assessed with radiologic imaging 
(plain radiographs and MRI).
The Oswestry Disability Index with self-evaluation 
questionnaire (ODI) was compiled by the patients just 
before	PV	(baseline)	as	well	as	at	the	time	of	the	 last	
interview (endpoint). Follow-up time varied from 3 
months	to	12	months	with	a	mean	of	10.0	±	3.5	months.
Statistical Methods
Because	 VAS	 and	 ODI	 scores	 did	 not	 follow	 a	
normal distribution, medians and their ranges were 
used as summary statistics and comparisons were per-
formed by non-parametric tests. A clinically relevant 
improvement or worsening in pain was defined as 
a	reduction	or	an	 increase	of	2	or	more	VAS	points,	
respectively,	 between	 time	 points.	 VAS	 scores	 and	
use of analgesic medications were compared using 
the Wilcoxon test. This test was also used to com-
pare baseline ODI with the best ODI score achieved 
by the patient during the follow-up period. Time to 
treatment failure was studied by the Kaplan Meier 
method from the date of the procedure to the time-
point at which the disease had worsened, the patient 
had undergone spinal surgery, a new vertebral frac-
ture had occurred, or the patient died from disease 
progression. Finally, the proportions of patients on 
different analgesic drugs at baseline and after one 
month from the procedure were compared by the 
Marginal Homogeneity test.
Statistical analyses were performed by the SPSS 
Version	 17	 statistical	 package	 (IBM;	 Chicago,	 IL,	 USA)	
and significance was set at P	<	0.05.
Results
All the procedures were successfully performed 
without	 clinical	 complications.	 VAS	 score,	 ODI	 score,	
and information on use of analgesics were available for 
all 40 patients before, one month, and three months 
after the procedure. Six- and 12-month determinations 
of	VAS	score,	ODI	score,	and	use	of	analgesics	could	be	
obtained in 36 and 22 patients respectively. Six patients 
died from disease progression: 3 between 3 and 6 
months, and 3 between 6 and 12 months from the pro-
cedure. One patient underwent surgical treatment be-
tween one and 3 months from the procedure because 
of disease progression. Three patients had experienced 
a new vertebral fracture due to new metastases be-
tween one and 3 months after the procedure (myeloma 
and breast cancer metastasis). Eleven patients alive and 
without events did not have the 12-month assessment 
because of short follow-up. Figure 4 shows the median 
VAS	values	at	different	time	points.	Before	the	proce-
dure,	the	median	VAS	score	was	10	(range	6	– 10) and 
Fig. 4. Boxplots of  VAS scores at various time points. The 
horizontal line in the middle of  each box represents the 
median of  the scores; the length of  the box represents the 
interquartile range; and the whiskers represent smallest and 
highest values that are not outliers. Outliers (values between 
1.5 and 3 box lengths) and extreme values (values that are 
more than 3 box lengths away) are indicated by an open circle 
and asterisk, respectively. The difference between baseline and 
one month value was statistically significant by the Wilcoxon 
test.
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dropped to one (range 0 – 3, P < 0.001) one month post-
procedure (Fig. 4). All patients achieved a clinically rel-
evant benefit on pain at one month defined as a drop 
in	the	VAS	score	of	at	least	2	points	following	the	pro-
cedure. A total of 12 patients experienced a treatment 
failure (see the definition in the statistical methods). 
Pain significantly worsened in 4 of 40 patients between 
one and 3 months after the procedure (8%). Except 
for 2 patients undergoing vertebral surgery (both at 
3 months from the procedure) and 6 patients dying 
from disease progression, no clinically relevant worsen-
ing	of	VAS	scores	was	seen	in	patients	with	follow-up	
data	 available	 (Fig.	 5).	 The	 proportion	 of	 patients	 in	
each category of pain medications, before and after 
the procedure, is summarized on Table 1. All patients 
Table 1. Change in the use of  analgesic medications before and one month after the procedure.
Type of  analgesic medication Pre-Procedure Number (%) Post- Procedure Number (%)
None 0 24 (60)
NSAIDS 1 (2) 16 (40)
Oral opiates 8 (20) 0
Transdermal or parenteral opiates 31 (78) 0
Fig. 5. Kaplan Meier estimate of  time to pain worsening. As 
all patients had a clinically meaningful improvement in pain 
(reduction of  at least 2 VAS points) at one month from the 
procedure, time 0 corresponds to the one month assessment.
on opiates, either transdermal or parenteral, could be 
switched	 to	NSAIDS	 (15,	 40%)	 or	 no	 treatment	 at	 all	
(25,	60%).	The	median	ODI	score	at	baseline	was	82.2%	
(range	 54.4%	 – 88.8%) and dropped to 4.1% during 
follow-up after the procedure (P < 0.001).
In 7 out of 43 (16.3%) treated vertebrae a bone 
cement leakage was detected by post-procedural CT: 2 
leakages	were	noted	in	the	disc,	whereas	5	occurred	in	
the paravertebral tissues or draining veins; no leakages 
were demonstrated inside the spinal canal.
Among the 37 patients who wore a brace before 
intervention, none required a brace after vertebral 
augmentation.
discussion
The treatment of painful vertebral metastases is 
a major therapeutic challenge. Radiation therapy is 
only modestly effective with marginal durability (18). 
Further, previously radiated vertebral levels are at el-
evated risk for collapse with potentially devastating 
neurologic consequences (19,20). This study shows that 
percutaneous vertebral augmentation using the novel 
coil-shaped PEEK Kiva implant is feasible, effective, 
and may reduce the risk of PMMA extravasation in the 
treatment of painful osteolytic vertebral metastases 
with diffuse cortical bone involvement. The results of 
this study are novel in that the Kiva implant represents 
a new therapeutic option for the treatment of painful 
vertebral metastasis where radiation therapy, tradi-
tional surgical stabilization, or balloon-based vertebral 
augmentation procedures may be contraindicated.
Chew et al (14) conducted a systematic review 
on the safety and efficacy of percutaneous vertebral 
augmentation for spinal metastases and myeloma. Al-
though vertebral augmentation reduced pain severity 
by 47% to 87%, serious complications were reported 
in up to 12% of patients.  The risk of cement extrava-
sation is also notably higher in malignancies due to 
increased vascularity and cortical disruption (8). Result-
ing complications may include intercostal neuralgia, 
radiculopathy, myelopathy, or spinal infections (21). 
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The Kiva System was designed to reduce and stabilize 
vertebral fractures by deploying a coiled PEEK implant, 
which is then augmented with cement. PMMA bone ce-
ment is injected through the lumen of the Kiva implant, 
which helps to contain and control the distribution of 
the cement. Once cured, the cement interlocks the im-
plant to the cancellous bone. With traditional kypho-
plasty and vertebroplasty procedures, PMMA is injected 
into cancellous bone but there is no mechanism for ce-
ment containment. Consequently, PMMA cement may 
leak laterally to the soft tissues, superiorly or inferiorly 
into the adjacent disc space, or posteriorly, where it may 
involve the exiting nerve root or the spinal canal (21).
A recent clinical study was conducted with the Kiva 
System in 26 patients (42 fractures) for treatment of 
vertebral compression fractures (22). Anterior cement 
extravasation was identified at 4.8% of levels with no 
reported intracanal extravasation or adverse clinical 
sequelae. These results compare favorably to the re-
ported range of cement extravasation rates of 7% to 
72% in previous studies (23-27).
The mechanism of pain amelioration with percu-
taneous vertebral augmentation is currently unknown 
although 2 main hypotheses prevail. Polymethyl meth-
acrylate cement stabilizes vertebral microfractures, 
which eliminates painful vertebral body and periosteal 
micromovements (6). In addition, the thermal polym-
erization of PMMA following injection ablates pain re-
ceptors in trabecular bone, in vertebral periostium, and 
in vascular structures (28). The combination of these 
2 proposed factors leads to immediate postoperative 
anterior	column	stability	and	pain	relief	(15).
conclusion
The Kiva System potentially represents a novel 
and effective minimally invasive treatment option for 
patients suffering from severe pain due to osteolytic ver-
tebral metastases. The novel design of the Kiva implant 
may reduce the risk for PMMA extravasation versus tra-
ditional vertebral augmentation procedures. Prospective 
studies in larger series are needed to validate the safety 
and effectiveness of this device in patients with vertebral 
metastasis. A large prospective randomized trial, the 
KAST	trial	(www.clinicaltrials.gov	NCT01123512),	is	near	
completion	 in	 the	United	 States	 evaluating	 this	device	
in osteoporotic fractures which should provide insight 
and evidence for the potential benefits of this device in 
vertebral fracture management. 
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